Search PubMed⌕ Search

Biomedical subjects

R Aston

Publications and source records attributed to R Aston.

At least 37 records · Page 2Linked to original sources
PubMed1990

The proportion of glycosylated prolactin in serum is decreased in hyperprolactinemic states.

The proportion of serum PRL that is glycosylated has been determined, and the effects of physiological and pathological hyperprolactinaemia on this proportion have been examined. Glycosylated and nonglycosylated PRL were immunoprecipitated from serum and subjected to polyacrylamide gel electrophoresis under reducing and dissociating conditions. Separated proteins were then transferred to nitrocellulose paper by electroblotting and detected immunologically with anti-PRL antiserum and 125I-labeled protein-A, followed by autoradiography. The proportion of total monomeric PRL present in the glycosylated form was then estimated by densitometric scanning of autoradiograms. In normal individuals glycosylated PRL was predominant, accounting for about 72% of the circulating monomeric PRL. This proportion was markedly decreased (ranging from undetectable to about 60%) in the serum of women who were pregnant or were lactating postpartum and also in patients with hyperprolactinemia caused by a pituitary tumor. The results suggest that under basal conditions the majority of PRL secreted from the pituitary is glycosylated, but with physiological or pathological hyperprolactinemia the capacity for glycosylation is exceeded.

Adult↗
PubMed1990

Induction of lactogenic receptors in liver of hypophysectomized rats treated with bovine growth hormone-monoclonal antibody complexes.

Male hypophysectomized rats treated with bovine (b)GH-monoclonal antibody complexes showed enhanced weight gain compared with animals treated with bGH alone over a 12-day treatment period. Liver microsomes prepared from animals showing enhanced weight gain exhibited increased specific binding of human (h)GH. Studies on the specificity of these binding sites showed that they were lactogenic, 125I-labelled hGH being displaced by ovine prolactin, but not by non-mammalian growth hormones. In this respect they were similar to lactogenic binding sites in the liver of pregnant rats. Monoclonal antibodies to hGH blocked binding to lactogenic receptors to different extents. The pattern of such inhibition was similar, but not identical, for the receptors induced in hypophysectomized rats and those from pregnant rat liver. The evidence available suggests that the lactogenic receptors induced by bGH-monoclonal antibody complexes are not directly involved in the enhancement of growth.

Animals↗
PubMed1990

Enhancement of bovine growth hormone activity by antibodies against growth hormone peptides.

The biological activity of growth hormones can be enhanced by complexing with monoclonal antibodies of appropriate specificity. In order to define the regions associated with the phenomenon, site-directed antisera to ovine GH (oGH) were prepared by vaccination of sheep with synthetic peptides. Peptides from six distinct regions of the oGH molecule raised antibodies which recognized the hormone in solid-phase radioimmunoassay; however, only one peptide elicited high-affinity antibody as determined by liquid-phase assay. This peptide, corresponding to amino acid sequence 35-53, resulted in circulating hormone antibody in the majority of vaccinated sheep. Immunoglobulin prepared from the serum of immunized animals produced an enhancement of the somatotrophic activity of exogenously administered GH in dwarf mice as determined by the incorporation of [35S]sulphate into costal cartilage. The identification of an antigenic peptide sequence from oGH/bovine GH which elicits enhancing antisera, raises the possibility of a growth-promotion vaccine.

Animals↗
PubMed1989

Antibody-mediated enhancement of hormone activity.

The enhancement of hormone activity by antibodies has been known for many years; however, investigation into the molecular basis of the phenomenon has only recently begun. A number of mechanisms for this enhancement, including "buffering" or slow release, bivalency and Fc region, and conformational and receptor "restriction" effects, have been documented or proposed. The availability of panels of monoclonal antibodies of distinct combining site specificity have aided in these studies and contributed substantially to our understanding of hormone-receptor interactions.

Animals↗
PubMed1989

Potentiation of growth hormone activity in sheep using monoclonal antibodies.

Monoclonal antibody OA11 was raised against ovine GH; its effects on GH activity were examined in a target species relevant for animal production in vivo. The monoclonal antibody was found to enhance the galactopoietic response to exogenous GH in adult lactating ewes and also to potentiate the diabetogenic activity of both exogenous and endogenous GH in ewe lambs. Thus it was shown that GH activity may be manipulated above its usual dose-response range in normal, intact animals of commercial importance via immunological means.

Animals↗
PubMed1988

Bioactivity and immunoactivity of growth hormone during dynamic testing of patients with acromegaly.

We have used the Nb2 cell proliferation bioassay for lactogenic hormones to investigate the biological activity of hGH in sera of patients with acromegaly. The specificity of the assay has been improved by the use of monoclonal antibodies to block the activity of individual lactogenic hormones. Disease activity in patients was assessed by scoring signs and symptoms, and by measuring IGF-I concentrations in some patients. Patients with a wide spectrum of disease activity were studied using a TRH test. hGH concentrations were measured by bioassay, RIA and immunoradiometric assay (IRMA) at 0, 20 and 60 min after injection of TRH. There was a high degree of correlation between log10 of all hGH concentrations measured by bioassay and RIA (r = 0.995, P less than 0.0001), between bioassay and IRMA (r = 0.990, P less than 0.0001), and between RIA and IRMA (r = 0.995, P less than 0.0001). In contrast to previous reports, we found no evidence for changes in the bioactivity of hGH secreted after pituitary stimulation.

Acromegaly↗
PubMed1988

Monoclonal antibody enhancement of the effects of human growth hormone on growth and body composition in mice.

Dwarf mice were treated for 10 days with phosphate-buffered saline (PBS), human growth hormone (hGH) or hGH with monoclonal antibody EB1 (hGH/MAB-EB1); for each treatment there were three groups which received 50, 75 or 100% of the amount of food eaten when available ad libitum. The PBS control groups lost more or gained less weight than equivalent groups receiving hGH alone, and mice given hGH/MAB-EB1 showed a greater weight gain than those in comparable groups receiving hGH alone. When weight gain or loss was expressed as g/g food eaten, groups treated with hGH gained more or lost less than the PBS groups. Similarly, weight gain/g food was significantly greater in hGH/MAB-EB1 animals than in the comparable groups given hGH alone. A similar pattern of response was observed for increases in tail length and uptake of 35SO42- into costal cartilage in vivo. For mice given hGH alone, fat content was decreased compared with that in the equivalent group given PBS, and mice treated with hGH/MAB-EB1 had less fat than the equivalent group given hGH alone. Administration of hGH alone caused a concomitant increase in protein content and body weight such that, compared with mice given PBS, there was no significant increase in protein as a proportion of body weight. However, hGH/MAB-EB1 caused an increase in whole body protein which was significantly greater than that for the equivalent group given hGH alone, when expressed as per cent body weight. Monoclonal antibody EB1 has been shown to enhance the actions of hGH on growth and body composition in Snell dwarf mice and to increase food conversion efficiency.

Animals↗
PubMed1987

Monoclonal antibodies to bovine growth hormone potentiate effects of the hormone on somatomedin C levels and growth of hypophysectomized rats.

Bovine growth hormone (50 micrograms/day) elevated somatomedin C levels in plasma of hypophysectomized rats: the effect was seen 12 h after the first injection and was sustained throughout a 7-day treatment period. When monoclonal antibodies to bovine growth hormone were administered with the hormone the stimulation of somatomedin C levels was markedly enhanced, as were effects on body weight. Each one of a panel of 7 monoclonal antibodies potentiated the actions of the hormone on growth and somatomedin C levels, though the extent and pattern of potentiation varied considerably from one antibody to another. Effects on growth and somatomedin C levels correlated fairly well, though there were some discrepancies.

Animals↗
PubMed1987

Heterogeneity of growth-hormone receptors detected with monoclonal antibodies to human growth hormone.

The specificity of hormone-receptor interactions has been examined with the aid of monoclonal antibodies (MABs) (EB1, EB2, QA68 and NA71) defining four non-overlapping antigenic determinants on human growth hormone (hGH). The results indicate that growth-hormone receptors in liver obtained from different sources differ with regard to their affinities and relative numbers; they may also differ with respect to the region of the growth-hormone molecule to which they bind. Antibody NA71 effectively inhibited hormone binding to all receptor preparations tested, although with various degrees of potency. Monoclonal antibody EB1 demonstrated a graded inhibition with respect to its ability to block 125I-hGH binding to receptors from various sources, the maximum inhibition being seen in receptor preparations from mouse and ovine liver and the minimum in rat liver. MABs EB2 and QA68 also showed various abilities to inhibit hormone-receptor interaction, depending on the origin of the receptor preparation. Furthermore, the receptor-binding characteristics of hormone-antibody complexes were dependent on whether the binding-site preparation was derived from pregnant, lactating or 'normal' animals. A particularly striking difference between the ability of hormone-MAB complexes to bind to receptors from different sources was seen for microsomes (microsomal fractions) derived from livers of animals of the 'Little' mouse strain. These animals become progressively obese, and it was shown that MABs were considerably more effective in inhibiting 125I-labelled hGH binding to microsomes from phenotypically obese mice than to those derived from their non-obese littermates. The results can be explained by the presence of multiple receptor types for GH, the relative proportions of which vary according to the physiological state of the animal, and possibly between species.

Animals↗
PubMed1987

Is there an interleukin 2 inhibitor in human serum?

Normal mouse serum has been shown to contain an inhibitor of interleukin 2 (IL-2). Here we report that a molecule with similar activity cannot be found in normal human serum (NHS). Although NHS inhibited the IL-2-dependent proliferation of mouse CTLL cells, as expected of an IL-2 inhibitor, it also had inhibitory activity on IL-3-dependent cells and was cytolytic to IL-2-independent mouse cells as measured by a 51Cr release assay, indicating a nonspecific effect. In addition, NHS had no effect on the IL-2-dependent proliferation of human peripheral blood T-cell blasts. Fractionation of NHS by size exclusion HPLC failed to separate cytolytic activity from any putative true IL-2 inhibitor activity. The cytolytic component was not related to immunoglobulin since it had a molecular weight of 50,000 to 60,000 and was not bound by protein-A-Sepharose. However, its molecular weight, heat lability, and trypsin sensitivity suggest it to be a protein.

Blood Proteins↗
PubMed1987

Enhancement of bovine growth hormone activity in vivo by monoclonal antibodies.

Monoclonal antibodies (MAbs) prepared against ovine growth hormone (oGH) and recognizing several distinct or related specificities on bovine growth hormone (bGH), have been shown to strikingly enhance the growth promoting properties of the hormone in vivo as determined by 35SO2-4 incorporation in cartilage. The phenomenon is dependent on both hormone and antibody dose and is saturable in the presence of excess antibody. Competition binding analysis between pairs of antibodies has shown that they define distinct antigenic regions on bGH of which one is represented by four MAbs. The most potent growth enhancement was associated with a group of three MAbs (OA11, OA12 and OA13) binding to topographically closely related sites. Another MAb (OA14) with a specificity similar to OA11 and OA13 as defined by competition assay failed to enhance bGH activity. Two antibodies binding to a further two sites (OA15 and OA16) demonstrated modest growth enhancement activity when in complex with bGH, whereas the binding of another antibody (OA17) did not significantly affect hormonal activity. Univalent antibody fragments (Fab) derived from MAb OA11 were equi-potent to the bivalent form of the antibody in the enhancement of bGH activity. Determination of the effects of the different MAbs on the binding of 125I-bGH to liver microsome receptors revealed substantial increase in specific binding (3.5-fold) and is associated with some growth enhancing MAbs. However, not all growth enhancing MAbs increased receptor binding and in the case of one, OA16, clear cut inhibition of receptor binding was observed. Tentative conclusions have been drawn on the possible underlying mechanisms of the MAb mediated enhancement phenomenon.

Animals↗
PubMed1987

Monoclonal antibodies can enhance the biological activity of thyrotropin.

In this work we demonstrate that monoclonal antibodies (MABs) to TSH can enhance the biological actions of TSH in vivo. Hypopituitary Snell dwarf mice were injected with TSH (25, 50, or 100 mU/day) alone or complexed with MAB-GC73 once per day for 5 days; control animals received PBS. Radioactive sulfate (35SO4(2-)) was also injected on the fifth day and animals were killed 20 h later. Thyroids were removed for histology, blood taken for T4 estimations by RIA, and 35SO4(2-) uptake into costal cartilage in vivo was measured. In control mice thyroid histology revealed small follicles comprised of small flattened epithelial cells with a high nuclear-cytoplasmic ratio; colloid was dark with little vacuolation. In animals treated with TSH alone there was moderate evidence of activation in most of these features. However, a marked response was noted in animals treated with TSH plus MAB-GC73; characteristically, there was little interfollicular tissue and the follicles, which were large and comprised of cuboidal cells, contained pale, finely vacuolated cytoplasm. Both TSH alone and TSH complexed with MAB-GC73 promoted a significant dose-dependent increase in serum T4 levels. The two higher doses of TSH plus MAB-GC73 promoted a significantly greater increase in serum levels of T4 than that in groups receiving the same dose of TSH alone. Uptake of 35SO4(2-) into costal cartilage showed a significant correlation with serum T4 levels. In similar experiments significant increases in salivary gland epidermal growth factor content of male dwarf mice were observed. This work demonstrated that MAB enhancement of hormone action is not restricted to human GH, suggesting a more general phenomenon.

Animals↗
PubMed1986

Potentiation of the somatogenic and lactogenic activity of human growth hormone with monoclonal antibodies.

Monoclonal antibodies of certain epitope specificity have been shown to produce a marked dose-dependent enhancement of the somatogenic and lactogenic activity of human GH (hGH). Two antibodies (EB1 and EB2), binding to distinct antigenic determinants and expressed on both hGH and human chorionic somato-mammotrophin (hCS), significantly enhanced the hGH-stimulated uptake of 35S-labelled sulphate into cartilage. Similarly, these antibodies enhanced the lactogenic activity of both hGH and hCS in the pigeon crop sac test. Two hGH specific monoclonal antibodies (QA68 and NA71), defining a further two epitopes, exhibited only modest enhancing or inhibitory activity in these assays, whereas the binding of certain combinations of monoclonal antibodies resulted in either reversal of enhancement or inhibition of hormone activity. Univalent antibody fragments derived from EB1 were as enhancing as the intact antibody indicating that bivalency dependent mechanisms were not involved in the phenomenon. Enhancing monoclonal antibodies were relatively poor inhibitors of 125I-labelled hGH binding to liver microsomal receptors, which is in contrast with their previously described property of potent suppression of hGH interaction with lymphoid cell receptors. It is tentatively concluded that 'restriction' of hormone binding to particular hGH receptors, relevant to somatic growth or lactogenic activity, may play a role in the enhancement phenomenon of hGH in vivo.

Animals↗
PubMed1986

Determination of the activity of clinical grade human growth hormone preparations by in vivo bioassay, in vitro cell proliferation assay and solid phase radioimmunoassay.

Preparations of clinical grade human growth hormone (hGH) have been examined for activity by an in vitro bioassay using NB2 lymphoma cells and by a monoclonal antibody (NA 71)-based radioimmunoassay. The activities observed have been compared with those obtained by the in vivo growth bioassay performed in mice of the Snell dwarf strain. The two in vitro assays correlated well with each other for specific preparations of hGH, although non-parallelism was observed between different preparations of the hormone. Some preparations of hGH were highly potent in the NA 71 immunoassay, but not in the NB2, cell-proliferation assay, suggesting the presence of antigenically active but biologically inactive hormone. Chromatographic studies on early hGH preparations revealed the presence of dimetric, trimetric and aggregated hormone as well as small quantities of prolactin. These were studied individually and shown to diverge in potency in the respective assays. It is concluded that the correlations between the in vivo bioassay in dwarf mice and the in vitro assays may be compromised by the varying potency of the constituent forms of the hormone and the non-linearity of the in vivo growth assay.

Animals↗
PubMed1985

Topographic and functional assay of antigenic determinants of human prolactin with monoclonal antibodies.

Six distinct antigenic determinants were identified on human prolactin (hPRL) by competition assays with murine monoclonal antibodies (MABs). The affinity of binding and the cross-reactivity of the antibodies with two non-primate prolactins was also determined. Binding of 125I-hPRL to MAB-coated microtitre plates in the presence of a second MAB resulted in either inhibition or enhancement of antigen binding to the plate. These results were interpreted in terms of conformational changes to epitopes, induced allosterically by the binding of a second MAB to the antigen. The topographic relationship of epitopes to the biologically active regions on the hormone was examined on the basis of the neutralizing potency of MABs in the proliferation of the prolactin-dependent cell line NB2. The NB2 growth-inhibitory activity was restricted to three distinct epitopes (NE02/6, 1208 and NE03) but absent from three other MABs tested (QB01, WC01/3 and 1200). On the basis of the competition and functional studies, an elemental scheme of the topographic localization of epitopes is presented. The experimental approach employed may contribute to studies on the allocation of biologically active sites on protein hormones.

Animals↗